Increased binding sites for "peripheral-type" benzodiazepine receptor (PTBR) ligands have been described in a wide range of neurological disorders including both human and experimental epilepsy. This study was undertaken to assess PTBR expression in relation to the presence of hippocampal sclerosis in human temporal lobe epilepsy (TLE). For this purpose, hippocampal CA1 subfields were dissected from surgical samples from patients with therapy-refractive TLE with (n = 5) or without (n = 2) hippocampal sclerosis and from age-matched nonepileptic postmortem controls (n = 5). PTBR expression was assessed by immunohistochemistry and reverse-transcription polymerase chain reaction. Receptor sites were evaluated using an in vitro binding assay and the selective PTBR ligand [ 3 H]PK11195. Epileptic patients with hippocampal sclerosis showed increases in PTBR binding sites, immunoreactivity, and mRNA expression compared to both nonsclerotic TLE patients and postmortem nonepileptic controls. Induction of PTBR expression and binding sites were directly correlated with the presence of hippocampal sclerosis and the accompanying reactive gliosis.
INTRODUCTION
The "peripheral-type" benzodiazepine receptor (PTBR) is a multimeric complex found mainly on the outer mitochondrial membrane of astrocytes (Anholt et al., 1986; Basile and Skolnick, 1986) . PTBR may also be colocalized with activated microglia in injured brain tissue (Kuhlmann and Guilarte, 2000) . PTBR is composed of three subunits, an 18 KDa isoquinoline carboxamide-binding protein (IBP), a 34 KDa voltage-dependent anion channel, and a 30 KDa adenine nucleotide carrier. PTBR has been implicated in various functions, such as steroidogenesis, respiration, cell growth, and differentiation, and in response to stress. PTBR expression is increased following brain injury and this increase in PTBR has been used as an indication of neuronal damage or loss in several neurodegenerative disorders, such as Alzheimer's disease (Diorio et al., 1991) , Huntington's disease (Messmer and Reynolds, 1998 ), Wernicke's encephalopathy (Desjardins et al., 1999) , multiple sclerosis (Banati et al., 2000) , and stroke-induced brain injury (Raghavendra Rao et al., 2000; Stephenson et al., 1995) . Increased PTBR expression in these conditions has been associated with both microglial activation and reactive astrogliosis.
An association between alterations of PTBR and epilepsy has been proposed for some time. Epileptic patients manifest increased binding sites for PTBR ligands in blood mononuclear cells (Caldiroli et al., 1997; Ferrarese et al., 1996; Larkin et al., 1993) as well as in brain (Beaurain et al., 1994; Johnson et al., 1992) . In addition, both EL (epileptic mice; Nakamoto et al., 1996) , and kainate-induced epileptic rats (Benavides et al., 1987) show increased brain densities of PTBR sites. It was suggested that these increases in PTBR sites were either the consequence of the epileptogenic process per se or resulted from the gliosis accompanying neuronal cell loss in hippocampus of epileptic animals.
The aim of this study was to measure PTBR expression in surgically excised samples of hippocampus from patients with temporal lobe epilepsy (TLE) with or without hippocampal sclerosis. PTBR binding sites were assessed by an in vitro binding technique utilizing the highly selective ligand [ 3 H]PK11195. Increased PTBR expression was visualized using immunohistochemistry and PTBR gene expression was measured by semiquantitative reverse-transcription polymerase chain reaction (RT-PCR).
MATERIALS AND METHODS

Patients
Patients with intractable epilepsy (n = 5) suffered from complex partial seizures and the epileptic focus was localized to the temporal lobe in all patients as revealed by physical examination, magnetic resonance imaging, and long-term video monitoring. The hippocampus was removed surgically from these patients in order to achieve seizure control. Informed consent was obtained for all procedures. Hippocampal samples were rapidly frozen for molecular studies or immersion-fixed in phosphate-buffered saline (PBS) for neuropathological evaluation and subsequent correlative analysis. Epileptic patients with nonsclerotic hippocampus (n = 2), as well as postmortem hippocampus from neuropathologically confirmed normal patients (n = 5), were used as nonepileptic controls. CA1 region was microdissected from frozen samples according to the atlas of Paxinos and Watson (1986) and frozen at −80
• C until RNA extraction.
[ 3 H]PK11195 Binding Assay
Membrane suspensions were prepared as described previously (Rao and Butterworth, 1997) with slight modifications. Briefly, each individual sample was homogenized in 100 volumes of ice-cold 50 mM Tris-HCl buffer (pH 7.5), with 5 up-and-down strokes of the glass-Teflon pestle. The homogenates were centrifuged at 40,000 g for 20 min and the pellet was resuspended in the initial volume of buffer and stored as aliquots at −80
• C. Membrane protein concentrations were determined by the methods of Lowry et al. (1951) . Aliquots of membrane suspension (400 µL, 0.3-0.6 mg/mL of protein) were incubated for 60 min at 4
• C with [ 3 H]PK11195 (specific activity 86 Ci/mmol) in a final volume of 500 µL. Nonspecific binding was defined in the presence of 1 µM unlabeled PK11195 (RBI). The incubation was stopped by dilution with ice-cold buffer, the samples were filtered under vacuum through Whatman GF/B filters using a Millipore harvester, and the filters were washed twice with 4 ml of ice-cold buffer. Filterbound activity was extracted into 4.5 ml of Ultima-Gold (Packard), and then determined by liquid scintillation counting at 40% efficiency. Saturation binding data were analyzed by nonlinear curve fitting, using the program GraphPad Prism (GraphPad Software, Inc., San Diego, CA). With this program, values for K d and B max are obtained by fitting curves to the data with the use of the equation 
Immunohistochemistry
Frozen sections (6 µM) were fixed with methanol for 2 min at −20
• C. The cell membranes were then permeabilized in PBS containing 1% Triton X-100 for 30 min at room temperature. The sections were rinsed with PBS and incubated with 0.3% H 2 O 2 for 5 min to inactivate endogenous peroxidase. Nonspecific sites were blocked in PBS containing 0.1% Triton X-100 (PBST) and 1.5% heat-inactivated goat serum for 30 min. Sections were incubated overnight at 4
• C, with a mouse monoclonal antibody (1 µg/mL) directed against human IBP (Sanofi Recherche, Montpellier, France) or HLA-DR, a human class II antigen of the major histocompatibility complex (PharMingen, NJ). After washing with PBST, sections were incubated with biotinylated goat antibody against mouse IgGs (Vector laboratory, CA) at a 1:200 dilution for 30 min at room temperature. Sections were washed with PBST and incubated with an avidin-biotin-peroxidase complex (Vectastain, Vector laboratory, CA) at a 1:500 dilution for 30 min. After washing with PBST, bound immunoglobulins were detected by incubation with 0.1 M Tris-HCl (pH 7.4) containing 0.5 mg/mL 3,3 -diaminobenzidine-HCl and 0.01% hydrogen peroxide.
RNA Extraction
Total RNA was extracted using TRI Reagent (MRC, Inc., Ohio) according to the manufacturer's protocol. Putative contaminating DNA was eliminated by adding 100 U of RNase-free DNase I per 50 mg of total RNA at 37
• C for 1 h. Purified RNA was then extracted with phenol, precipitated with ethanol, and resuspended in diethylpyrocarbonatetreated water. RNA samples were kept at −70
• C until use.
RT-PCR Analysis
β-Actin was used as an internal standard to monitor loading variations. Total RNA (0.5 mg) was mixed with 10 mM Tris-HCl (pH 8.3), 1.0 mM MgCl 2 , 50 mM KCl, 0.01% (w/v) bovine serum albumin, 100 mM dNTPs, primers at 1 mM each, AMV reverse transcriptase (80 U/mL), Taq DNA polymerase (20 U/mL), and 50 mCi/mL [α 32 P]dCTP (3000 Ci/mmol), for a total reaction volume of 50 mL. The reactions were initially carried out at 50
• C for 15 min, followed by PCR at 95
• C for 30 s, at 62
• C for 45 s, and at 72
• C for 1 min. Amplification efficiency conditions were determined after a kinetic study, to ensure all experiments were performed within the exponential phase of amplification where PCR product remains proportional to initial template concentration (data not shown). β-Actin and PTBR (IBP subunit) were amplified for 18 and 33 cycles, respectively. After amplification, the samples were electrophoresed onto 9% polyacrylamide gels, dried, and autoradiographed at −70
• C with an intensifying screen. Each band was excised and Cerenkov radiation was quantitated using a β-counter. Oligonucleotide primers were designed using the PRIME program (Genetic Computer Group, Wisconsin) and synthesized by the Sheldon Biotechnology Center (McGill University, Quebec) based on the following GeneBank accession numbers: X00351 (β-Actin; Ponte et al., 1984) and L21951-L21954 (PTBR; Lin et al., 1993) . The forward and reverse primer sequences were as follows: GACCTGACTGACTACCTCAT and AGACAGCACTGTGTTGGCGT (β-actin, 350 bp); and GCCCTTCCCGGAGCGTGCC and CGGCGTACCAGCGGAGAC (PTBR, 164 bp). The specificity of the oligonucleotide primers was verified using the program BLASTN (National Center for Biotechnology Information, Bethesda, MD).
Statistical Analysis
Data are expressed as means ± SEM. A probability of less than 5% ( p < 0.05) was considered to indicate statistical significance. All statistical analyses were performed using the computer software GraphPad Prism. Statistical significance of differences between the groups was determined with the unpaired, two-tailed Student's t test.
RESULTS
Saturation binding curves for the binding of the PTBR ligand [
3 H]PK11195 to crude synaptic membrane preparations from controls and from TLE patients obtained at autopsy are shown in Fig. 1 . A significant 2.5-fold increase ( p < 0.05) in binding sites was observed in TLE samples. B max and K d values for TLE patients were 694 ± 61.7 fmol/mg protein and 2.15 ± 0.5 nM, respectively. In comparison, B max and K d values for controls were 282 ± 25.0 fmol/mg protein and 0.94 ± 0.29 nM, respectively.
Hematoxylin-eosin staining of sections from TLE patients showed, in five of seven cases, an almost complete loss of neurons from the CA1 subfield (Fig. 2) . In all five cases PTBR immunolabeling studies revealed increased immunoreactivity confined to astrocytes in these sections (Fig. 2, panel d) . At the mRNA level, TLE patients with hippocampal sclerosis showed significantly increased (by 66%, p < 0.01) PTBR expression compared to two patients with TLE who did not manifest hippocampal sclerosis (Fig. 3) .
There was no evidence for the appearance of activated microglia/macrophages in the TLE patient samples used in this study as visualized using HLA-DR immunoreactivity (data not shown).
DISCUSSION
Results of the present study reveal significant increases in densities of binding sites for the PTBR ligand [ 3 H]PK11195 in dissected hippocampal CA1 subfields from five patients with TLE. In all cases, increased PTBR sites were associated with severe neuronal loss (hippocampal sclerosis) and reactive gliosis. These findings confirm and extend those of previous studies which observed increased PTBR sites in blood mononuclear cells (Caldiroli et al., 1997; Ferrarese et al., 1996; Laikin et al., 1993) and brain (Beaurain et al., 1994; Johnson et al., 1992) . Novel findings in the present study are those of increased PTBR sites in material from TLE patients with hippocampal sclerosis compared to similar material from patients with no pathological evidence of hippocampal sclerosis. Immunohistochemical studies revealed increased PTBR immunolabeling in CA1 subfield of TLE patients with hippocampal sclerosis. Increased immunolabeling was particularly localized on astrocytic elements suggesting that the increased PTBR signal was the consequence of astrogliosis which accompanied neuronal cell loss in TLE. Similar findings of increased PTBR sites coincident with astrocytic proliferation in the presence of neuronal loss were previously reported in Alzheimer's disease (Diorio et al., 1991) and Wernicke's encephalopathy (Desjardins et al., 1999; Leong et al., 1996) . On the other hand, other disorders, such as multiple sclerosis (Banati et al., 2000) and stroke-induced brain injury (Stephenson et al., 1995) , have been described in which increased PTBR sites coincided with the appearance of activated microglia rather than astrocytes. As previously reported by others (Beaurain et al., 1994) , there was no evidence for a role of activated microglia activation in the samples used in the present study, suggesting that the hippocampal sclerosis in these patients was relatively longstanding.
Although unlikely (given the relatively low levels of expression of PTBR in nonsclerotic TLE patients observed in the present study), there is conceivably a role for PTBR activation in the pathogenesis of the epileptic process per se. PTBR mediates the transport of cholesterol across the mitochondrial membrane and subsequently plays a role in the synthesis of the so-called neurosteroids, some of which have agonistic properties at GABA-A and NMDA receptors (Compagnone and Mellon, 2000) . Activation of PTBR could therefore result in an imbalance between excitatory and inhibitory systems in the CNS (Majewska et al., 1987; Wu et al., 1991) . Alternatively, increased PTBR in TLE may represent an adaptive phenomenon in hippocampal fields aimed at increasing neuroinhibition via the synthesis of epalons, a class of neurosteroids with anticonvulsant properties shown previously to allosterically potentiate the effect of GABA on chloride conductance by the GABA-A receptor complex (Gee et al., 1995) .
Findings in the present study of a correlation between the increased expression of PTBR sites in vulnerable CA1 subfields of TLE patients with the presence of hippocampal sclerosis suggest that the Positron Emission Tomography (PET) ligand [ 11 C]PK11195 may be useful in imaging the degree of hippocampal damage in TLE patients similar to that previously proposed for imaging of the extent of brain lesions in Wernicke's encephalopathy (Leong et al., 1996) and multiple sclerosis (Banati et al., 2000) .
Other PET ligands such as [ 11 C]flumazenil ([ 11 C]FMZ) have been used extensively to evaluate the extent of neuronal loss in patients with refractory TLE. [
11 C]FMZ binds to the GABA-related central benzodiazepine receptor and can be used in vivo to detect remaining neurons in sclerotic hippocampi. In many cases, however, [
11 C]FMZ showed poor spatial correlation with neuronal cell loss and therefore has not been proven consistently helpful in localizing the epileptic foci (Koepp et al., 2000) . Autoradiographic studies in experimental model of Wernicke's encephalopathy revealed that increases in [ 3 H]PK11195 binding sites paralleled the topographic distribution of neuronal cell loss and reactive gliosis more accurately than changes in the densities of [ 3 H]FMZ binding sites (Leong et al., 1996) , suggesting that [ 11 C]PK11195 represents a more reliable PET ligand to evaluate neuronal cell loss. Further studies are clearly warranted in order to evaluate this possibility.
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